Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
24 Results for "
elastase release
" in MedChemExpress (MCE) Product Catalog:
Products (24)
24 Results for "elastase release" in MCE Product Catalog:
5
5 Cited Publications
Target:
Research Areas:
HCH6-1 is a potent and competitive dipeptide antagonist of Formyl peptide receptor 1 (FPR1). HCH6-1 inhibits chemotaxis, superoxide anion generation, and elastase release in human neutrophils specifically activated by fMLF (an FPR1 agonist). HCH6-1 has protective effects against acute lung injury (ALI) in vivo and can be used for the research of FPR1-involved inflammatory lung diseases .
4
Category:
Flavonoids Neurological Disease Flavones Rutaceae Plants Disease Research Fields Citrus Cancer
Target:
Target:
Research Areas:
Neutrophil elastase inhibitor 5 is an inhibitor of human neutrophil elastase (HNE), proteinase 3 (PR3) and sirt2, with IC50 values of 4.91, 20.69 and 2.42 μM, respectively. Neutrophil elastase inhibitor 5 inhibits superoxide anion production and elastase release in human neutrophils. Neutrophil elastase inhibitor 5 can be used for the research of neutrophil inflammatory diseases .
Cat. No.: HY-N13250
Cat. No.: HY-132132
CAS No.: 1234707-32-4
Target:
Research Areas:
Neutrophil elastase inhibitor 3 (compound 13), a benzoxazinone analog, shows effects on superoxide anion generation and exhibits as a neutrophil elastase (NE) inhibitor, with an IC50 of 80.8 nM for NE release .
Cat. No.: HY-N10450
CAS No.: 72755-19-2
Synonyms: 1-Ethoxycarbonyl-β-carboline
Target:
Cat. No.: HY-164429
CAS No.: 2418533-90-9
VIP236 is a small-molecule drug conjugate targeting αvβ3 integrin. VIP236 achieves tumor homing via specific binding to αvβ3 integrin and delivers its payload to the tumor microenvironment. The linker of VIP236 is cleavable by neutrophil elastase, which is highly expressed in the tumor microenvironment, to release the payload 7-ethylcamptothecin. This payload induces DNA damage by inhibiting topoisomerase 1, thereby exerting anti-tumor effects. VIP236 exhibits excellent plasma stability and tumor targeting property, with a tumor/plasma payload ratio 10-fold higher than that of the single administration. It effectively induces tumor regression, reduces metastasis formation, and shows good tolerance in mouse models. VIP236 has been used in studies related to non-small cell lung cancer, clear cell renal cell carcinoma, colon cancer, triple-negative breast cancer, small cell lung cancer, and metastatic solid tumors .
Cat. No.: HY-P4126
CAS No.: 113277-37-5
Cat. No.: HY-N3566
CAS No.: 55610-01-0
Target:
Cat. No.: HY-106899
CAS No.: 135947-75-0
Research Areas:
MK 287 is a potent, selective and orally active antagonist of platelet-activating factor receptor (PAFR). MK 287 can inhibit [3H]C18-PAF binding to human platelet, polymorphonuclear leukocyte (PMN) and lung membranes with K1 values of 6.1, 3.2, and 5.49 nM, respectively. MK 287 can inhibit PAF-induced aggregation of platelets in plasma or gel-filtered platelets and elastase release from PMNs with ED50 values of 56, 1.5 and 4.4 nM. MK 287 can be used for the research of cardiovascular disease, such as thrombosis .
Cat. No.: HY-N11564
CAS No.: 97399-89-8
Target:
Cat. No.: HY-N8447
CAS No.: 1891097-17-8
Target:
Cat. No.: HY-176403
CAS No.: 3058943-53-3
Target:
Research Areas:
FPR1 antagonist 3 (compound 10) is a potent and selective FPR1 antagonist. FPR1 antagonist 3 inhibits superoxide anion generation and elastase release with IC50s of 0.33 and 0.84 μM, respectively .
Category:
Cat. No.: HY-106899A
CAS No.: 143445-03-8
Synonyms: (rel)-L-680573
Research Areas:
(rel)-MK 287 ((rel)-L-680573) is a relative configuration of MK 287. MK 287 is a potent, selective and orally active antagonist of platelet-activating factor receptor (PAFR). MK 287 can inhibit [3H]C18-PAF binding to human platelet, polymorphonuclear leukocyte (PMN) and lung membranes with K1 values of 6.1, 3.2, and 5.49 nM, respectively. MK 287 can inhibit PAF-induced aggregation of platelets in plasma or gel-filtered platelets and elastase release from PMNs with ED50 values of 56, 1.5 and 4.4 nM. MK 287 can be used for the research of cardiovascular disease, such as thrombosis .
Cat. No.: HY-117811
CAS No.: 143490-81-7
Synonyms: L-680574
Research Areas:
(R,R)-MK 287 (L-680574) is a tetrahydrofuran derivative that potently inhibits the binding of [3H]C18-PAF to human platelets, polymorphonuclear leukocytes (PMNs), and lung membranes with Ki values of 6.1, 3.2, and 5.49 nM, respectively. (R,R)-MK 287 potently and selectively inhibits PAF-induced platelet aggregation (ED50=56 nM) and elastase release from PMNs (ED50=4.4 nM). (R,R)-MK 287 inhibits PAF-induced lethality in mice (ED50=0.8 mg/kg, po) and PAF-induced bronchospasm in guinea pigs (ED50=0.18 mg/kg) .
Cat. No.: HY-N17409
CAS No.: 1275622-19-9
Category:
Simple Phenylpropanols Phenylpropanoids Plants Compositae Guilandina minax (Hance) G. P. Lewis
Target:
Cat. No.: HY-N19660
CAS No.: 1642784-96-0
Target:
Cat. No.: HY-N19297
CAS No.: 57672-91-0
Synonyms: Prieurianin
Target:
Cat. No.: HY-125128
CAS No.: 83329-36-6
Target:
Research Areas:
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
